Advertisement
Research Article

The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years

  • Eric A. Ottesen mail,

    eottesen@taskforce.org

    Affiliation: Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia, United States of America

    X
  • Pamela J. Hooper,

    Affiliation: Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia, United States of America

    X
  • Mark Bradley,

    Affiliation: Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom

    X
  • Gautam Biswas

    Affiliation: Preventive Chemotherapy and Transmission Control, World Health Organization, Geneva, Switzerland

    X
  • Published: October 08, 2008
  • DOI: 10.1371/journal.pntd.0000317

About the Authors

Eric A. Ottesen, Pamela J. Hooper
Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia, United States of America
Mark Bradley
Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom
Gautam Biswas
Preventive Chemotherapy and Transmission Control, World Health Organization, Geneva, Switzerland

Corresponding Author

Email: eottesen@taskforce.org

Competing Interests

Dr. Mark Bradley currently works for GlaxoSmithKline.

Author Contributions

Conceived and designed the experiments: EAO PJH MB GB. Performed the experiments: EAO PJH MB GB. Analyzed the data: EAO PJH MB GB. Wrote the paper: EAO PJH MB GB.